Pantel AR, Ackerman D, Lee SC, Mankoff DA, Gade TP
The key difference is that Tirzepatide is already connected to approved prescription products in Canada, while Retatrutide is still an investigational triple-receptor peptide being studied in clinical trials
The medications covered under the Bridge program All four medications included in the program are in the GLP-1 family, which means they work by mimicking gut hormones to lower appetite, slow digestion, and regulate blood sugar, but theyre not identical
The two molecules sit in the same melanocortin neighbourhood, but their receptor profiles, evidence bases, regulatory histories, and sourcing cautions are materially different
Durakov Z, Trebatick B, Novotn V, itanov I, Breza J